{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:08:27Z","timestamp":1790312907654,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:00:00Z","timestamp":1665878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:00:00Z","timestamp":1665878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chongqing Science and Technology Commission","award":["cstc2019jcyj-msxmX0714"],"award-info":[{"award-number":["cstc2019jcyj-msxmX0714"]}]},{"name":"Chongqing Science and Technology Commission","award":["cstc2018jcyjAX0055"],"award-info":[{"award-number":["cstc2018jcyjAX0055"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81804086"],"award-info":[{"award-number":["81804086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing Health Committee","award":["ZY201802059"],"award-info":[{"award-number":["ZY201802059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction\/aim<\/jats:title><jats:p>Effects of low-dose interleukin-2 (IL-2) on the exocrine glandular glands of Sj\u00f6gren\u2019s syndrome are unknown. The aim of this study was to investigate the effects of low-dose IL-2 on salivary gland structure and function in a murine model of Sj\u00f6gren\u2019s syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Non-obese diabetic\/Ltj (NOD) mice were used as the animal model of Sj\u00f6gren\u2019s syndrome, and low-dose IL-2 or phosphate buffered saline was administered subcutaneously from 5\u00a0weeks of age, while ICR mice were used as controls. Some mice were sacrificed at 9\u00a0weeks of age, while the other mice that continued to receive treatment were sacrificed at 23\u00a0weeks. We determined the salivary flow rate of mice every 3\u00a0weeks during the intervention. After the mice were sacrificed, one submandibular gland was removed for pathological evaluation, while the other submandibular gland was used to measure the levels of 25 cytokines by Luminex technology. Cervical lymph nodes and spleens were examined by flow cytometry for the proportions of CD8<jats:sup>+<\/jats:sup>T cells and Treg cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results showed that the salivary flow rate of NOD mice was slower than that of control-group mice, and there were more pathological changes in the submandibular gland. The levels of many cytokines in the submandibular gland were elevated. The proportion of CD8<jats:sup>+<\/jats:sup>T cells in the cervical lymph nodes and spleens was increased; however, the proportion of Treg cells was decreased. After treatment with IL-2, the exocrine function of the salivary glands of mice was improved. IL-2 also promoted the proliferation of Treg cells in the cervical lymph nodes and spleens, but it did not alter the extent of lymphocyte infiltration in the submandibular gland. The levels of cytokines in the submandibular glands, as well as the proportion of CD8<jats:sup>+<\/jats:sup>T cells in the cervical lymph nodes and spleens, were unchanged significantly after IL-2 treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results demonstrate that treatment with low-dose IL-2 improves the secretory function of the exocrine glands of mice with Sj\u00f6gren\u2019s syndrome, but it does not reverse the structural damage of the exocrine glands.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12865-022-00524-1","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T11:02:32Z","timestamp":1665918152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1186","volume":"23","author":[{"given":"Junsong","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,16]]},"reference":[{"key":"524_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","volume":"68","author":"CP Mavragani","year":"2017","unstructured":"Mavragani CP. Mechanisms and new strategies for primary Sj\u00f6gren\u2019s syndrome. Annu Rev Med. 2017;68:331\u201343.","journal-title":"Annu Rev Med"},{"issue":"1\u20132","key":"524_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jaut.2011.12.006","volume":"39","author":"C Baldini","year":"2012","unstructured":"Baldini C, Talarico R, Tzioufas AG, et al. Classification criteria for Sjogren\u2019s syndrome: a critical review. J Autoimmun. 2012;39(1\u20132):9\u201314.","journal-title":"J Autoimmun"},{"key":"524_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/rheumatology\/kei107","volume":"45","author":"Y Alamanos","year":"2006","unstructured":"Alamanos Y, Tsifetaki N, Voulgari PV, Venet-sanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sj\u00f6gren\u2019s syndrome in north-west Greece, 1982\u20132003. Rheumatology (Oxford). 2006;45:187\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"524_CR4","doi-asserted-by":"crossref","unstructured":"Mavragani CP, Moutsopoulos HM, The geoepidemiology of Sj\u00f6gren's syndrome. Autoimm Rev 2010;9(5):A305\u2013A310, ISSN 1568-9972","DOI":"10.1016\/j.autrev.2009.11.004"},{"key":"524_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/03009740310004676","volume":"33","author":"SJ Bowman","year":"2004","unstructured":"Bowman SJ, Ibrahim GH, Holmes G, Ham-burger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sj\u00f6gren\u2019s syndrome in two general practices in Birmingham. UK Scand J Rheumatol. 2004;33:39\u201343.","journal-title":"UK Scand J Rheumatol"},{"issue":"S 118(3)","key":"524_CR6","first-page":"167","volume":"37","author":"S Fasano","year":"2019","unstructured":"Fasano S, Isenberg DA. Present and novel biologic drugs in primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol. 2019;37(S 118(3)):167\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"524_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15\u201325.","journal-title":"Arthritis Rheum"},{"key":"524_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7150\/ijms.17718","volume":"14","author":"T Both","year":"2017","unstructured":"Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness\u2013from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14:191\u2013200.","journal-title":"Int J Med Sci"},{"issue":"8","key":"524_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","volume":"12","author":"A Saraux","year":"2016","unstructured":"Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol. 2016;12(8):456\u201371.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"524_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jama.2010.1014","volume":"304","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sj\u00f6gren syndrome: a systematic review. JAMA. 2010;304(4):452\u201360.","journal-title":"JAMA"},{"issue":"10","key":"524_CR11","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","volume":"56","author":"EJ Price","year":"2017","unstructured":"Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s Syndrome. Rheumatology. 2017;56(10):1828.","journal-title":"Rheumatology"},{"key":"524_CR12","doi-asserted-by":"crossref","unstructured":"Dong S, Hiam-Galvez K J, Mowery C T, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 2021;6(18)","DOI":"10.1172\/jci.insight.147474"},{"issue":"1","key":"524_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao M, Hao Z, Guo Y, et al. Long-term and low-dose il-2 therapy maintains the th17\/treg balance in peripheral blood of patients with primary sj\u00d6gren\u2019s syndrome. Ann Rheumatic Dis. 2018;77:689\u201390.","journal-title":"Ann Rheumatic Dis"},{"issue":"18","key":"524_CR15","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1073\/pnas.1103782108","volume":"108","author":"A McNally","year":"2011","unstructured":"McNally A, Hill GR, Sparwasser T, et al. CD4+ CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci. 2011;108(18):7529\u201334.","journal-title":"Proc Natl Acad Sci"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2014.01.030","volume":"51","author":"A Alunno","year":"2014","unstructured":"Alunno A, Carubbi F, Bistoni O, et al. CD4\u2212 CD8\u2212 T-cells in primary Sj\u00f6gren\u2019s syndrome: association with the extent of glandular involvement. J Autoimmun. 2014;51:38\u201343.","journal-title":"J Autoimmun"},{"issue":"10","key":"524_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3390\/cells8101234","volume":"8","author":"A Rose","year":"2019","unstructured":"Rose A, von Spee-Mayer C, Kloke L, et al. IL-2 therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4+ T cells in murine lupus nephritis. Cells. 2019;8(10):1234.","journal-title":"Cells"},{"issue":"7","key":"524_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19(7):665\u201373.","journal-title":"Nat Immunol"},{"key":"524_CR19","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Ann Rheumatic Dis. 2018;77:1838\u201340.","journal-title":"Ann Rheumatic Dis"},{"key":"524_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","volume":"17","author":"NR Maimela","year":"2019","unstructured":"Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J. 2019;17:1\u201313.","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"524_CR21","first-page":"1","volume":"51","author":"TS Kim","year":"2019","unstructured":"Kim TS, Shin EC. The activation of bystander CD8+ T cells and their roles in viral infection. Exp Mol Med. 2019;51(12):1\u20139.","journal-title":"Exp Mol Med"},{"issue":"4","key":"524_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670\u201384.","journal-title":"Immunity"},{"issue":"12","key":"524_CR23","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.4049\/jimmunol.178.12.8090","volume":"178","author":"T Maeno","year":"2007","unstructured":"Maeno T, Houghton AMG, Quintero PA, et al. CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol. 2007;178(12):8090\u20136.","journal-title":"J Immunol"},{"issue":"8","key":"524_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/ni1098","volume":"5","author":"VP Badovinac","year":"2004","unstructured":"Badovinac VP, Porter BB, Harty JT. CD8+ T cell contraction is controlled by early inflammation. Nat Immunol. 2004;5(8):809\u201317.","journal-title":"Nat Immunol"},{"key":"524_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaut.2013.06.004","volume":"45","author":"DM Gravano","year":"2013","unstructured":"Gravano DM, Hoyer KK. Promotion and prevention of autoimmune disease by CD8+ T cells. J Autoimmun. 2013;45:68\u201379.","journal-title":"J Autoimmun"},{"key":"524_CR26","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3389\/fimmu.2020.602823","volume":"11","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yang J, Tian J, et al. CD8+ T lymphocytes: crucial players in sj\u00f6gren\u2019s syndrome. Front Immunol. 2021;11:3632.","journal-title":"Front Immunol"},{"issue":"3","key":"524_CR27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor \u03b1-chains (CD25):breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151\u201364.","journal-title":"J Immunol"},{"issue":"12","key":"524_CR28","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.4049\/jimmunol.168.12.5979","volume":"168","author":"RS McHugh","year":"2002","unstructured":"McHugh RS, Shevach EM. Cutting edge: depletion of CD4+ CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol. 2002;168(12):5979\u201383.","journal-title":"J Immunol"},{"issue":"2","key":"524_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.184.2.387","volume":"184","author":"M Asano","year":"1996","unstructured":"Asano M, Toda M, Sakaguchi N, et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184(2):387\u201396.","journal-title":"J Exp Med"},{"issue":"9","key":"524_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1084\/jem.20100209","volume":"207","author":"Y Grinberg-Bleyer","year":"2010","unstructured":"Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9):1871\u20138.","journal-title":"J Exp Med"},{"issue":"1","key":"524_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02559-y","volume":"23","author":"LM Araujo","year":"2021","unstructured":"Araujo LM, Jouhault Q, Fert I, et al. Effects of a low-dose IL-2 treatment in HLA-B27 transgenic rat model of spondyloarthritis. Arthritis Res Ther. 2021;23(1):1\u20139.","journal-title":"Arthritis Res Ther"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-022-00524-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-022-00524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T14:28:54Z","timestamp":1678285734000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-022-00524-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,16]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1186\/s12865-022-00524-1","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,16]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is reported in accordance with ARRIVE guidelines. All animal protocols were approved by the Institutional Animal Care and Use Committee of Chongqing Hospital of Traditional Chinese Medicine, with approval code SYXK2020-0001. All animal experiments were carried out in accordance with the guidelines of the Experimental Animal Welfare and Ethics Committee of Chongqing Hospital of Traditional Chinese Medicine (the number of ethic approval: DWSY-LCY). All mice were sacrificed by exsanguination under anesthesia by 5% isoflurane. The sacrificed mice were processed by special departments. This study does not involve the use of human data or tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}